Gilead Earnings Fall Short, Hurt by Faltering Sales of Key Drugs

(Bloomberg) -- Gilead Sciences Inc. posted weaker-than-expected fourth-quarter earnings, as sales of some of its best-known drugs declined from a year earlier.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.